Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 10/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 9/20 | 0.69 |
| ▸ | CLK2 | P49760 | 8/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.62 |
| ▸ | CLK3 | P49761 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753237 | 0.82 | CLK1 (0.66) | CLK1DYRK1ACLK4DYRK1BCLK2 | |
| SCHEMBL16404646 | 0.80 | CLK4 (0.81) | CLK1DYRK1ACLK4DYRK1BCLK2 | |
| SCHEMBL3750394 | 0.80 | CLK1 (0.62) | CLK1DYRK1ACLK4DYRK1BCLK2 | |
| SCHEMBL3753808 | 0.80 | MAPK10 (0.70) | MAPK8MAPK10MEN1NPC1RAB9A | |
| SCHEMBL3758774 | 0.79 | MAPK10 (0.71) | MAPK8MAPK10JAK2 | |
| SCHEMBL13588445 | 0.79 | MAPK8 (0.82) | MAPK8MAPK10JAK2 | |
| SCHEMBL3751635 | 0.79 | CLK4 (0.71) | CLK1DYRK1ACLK4DYRK1BCLK2 | |
| SCHEMBL3753054 | 0.78 | CLK1 (0.66) | CLK1DYRK1ACLK4DYRK1BCLK2 | |
| SCHEMBL3755971 | 0.78 | MAPK10 (0.68) | MAPK8MAPK10SYKMEN1NPC1 | |
| SCHEMBL3756063 | 0.77 | MAPK8 (1.00) | MAPK8MAPK10JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-08-20 | — | — | US | disclosed |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-08-20 | — | — | US | disclosed |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-08-20 | — | — | US | disclosed |
| US-9018205-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018205-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018205-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2200436-B1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | CLK1 452/4885DYRK1A 580/4885CLK4 547/4885 |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | CLK1 452/4885DYRK1A 580/4885CLK4 547/4885 |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | CLK1 452/4885DYRK1A 580/4885CLK4 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.